FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

Science & Research
8

Latest Research on Zepbound

Frankie Bradley·6 months ago
Some interesting new research on Zepbound has been published recently and I wanted to discuss the findings with the community. The most notable recent study used a randomized controlled design with a decent sample size. The treatment group showed statistically significant improvements in the primary outcome measures compared to placebo, with a p-value well below 0.05. Effect sizes were in the moderate range, which is consistent with prior smaller studies. What I find particularly interesting is the secondary endpoint data. The study measured several biomarkers related to inflammation and oxidative stress, and Zepbound appeared to have favorable effects on multiple pathways simultaneously. This polypharmacology is unusual for a peptide of this size. The pharmacokinetic data from this study also provided useful practical information. Half-life measurements suggest that the commonly used dosing intervals are reasonable, though there may be room for optimization. One limitation worth noting: the study population was fairly homogeneous. We need data from more diverse populations before generalizing the findings too broadly. Additionally, the study duration was relatively short, so long-term efficacy and safety remain open questions. Overall this adds to a growing body of evidence supporting the utility of Zepbound, while also highlighting areas where more research is needed.

Comments (8)

Sage BaileyDEMO·6 months ago

The polypharmacology point is well made. Multi-target compounds are increasingly recognized as advantageous in complex metabolic conditions. The anti-inflammatory effects you mention in secondary endpoints could be driving clinical benefits independently of the primary mechanism.

0
Noel BlakeDEMO·6 months ago

I have been stacking Zepbound with another peptide for the last 8 weeks and the combination has been notably better than either alone in my experience. The synergy makes sense given their complementary mechanisms. Happy to share my specific protocol if anyone is interested.

5
Hunter CookDEMO·6 months ago

Real talk: Zepbound worked well for me but the cost is significant. For anyone considering it, I would suggest doing a proper cost-benefit analysis first. Calculate the total cost for a full protocol and honestly assess whether the expected benefits justify that investment.

6
Bay AllenDEMO·6 months ago

Interesting data. My Zepbound experience was somewhat different — I noticed effects earlier than you did, probably because I started at a higher initial dose. Trade-off was more pronounced side effects in week 1 that resolved by week 2. Neither approach is wrong, just different risk-reward profiles.

7
Reese CollinsDEMO·6 months ago

This thread has been incredibly helpful for understanding Zepbound. I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

2
Vale ForbesDEMO·6 months ago

One thing I wish more Zepbound discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

3
Beck ArcherDEMO·6 months ago

The homogeneous study population limitation is critical. Most of these trials are run in specific demographics. Age, sex, ethnicity, and baseline metabolic health all influence response. We need more diverse datasets before making broad recommendations.

0
Bailey ArnoldDEMO·6 months ago

I appreciate the balanced take. Too much discussion online is either uncritical hype or dismissive skepticism. The evidence supports utility within specific contexts but the limitations you outlined are real and should guide expectations.

0

Sign in to comment.